×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Why Personalis is one of the most innovative biotech companies of 2024
Fast Company
Fast Company has named cancer detection company Personalis as one of its most innovative biotech companies of 2024.
1 month ago
Personalis Full Year 2022 Earnings: EPS Misses Expectations
Yahoo Movies UK
Personalis ( NASDAQ:PSNL ) Full Year 2022 Results Key Financial Results Revenue: US$65.0m (down 24% from FY 2021). Net...
2 days ago
HC Wainwright Weighs in on Personalis, Inc.'s Q3 2024 Earnings (NASDAQ:PSNL)
Defense World
Read HC Wainwright Weighs in on Personalis, Inc.'s Q3 2024 Earnings (NASDAQ:PSNL) at Defense World.
3 days ago
Lake Street Initiates Coverage of Personalis (PSNL) with Buy Recommendation
Nasdaq
Fintel reports that on April 30, 2024, Lake Street initiated coverage of Personalis (NasdaqGM:PSNL) with a Buy recommendation.
2 weeks ago
Personalis: Q1 Earnings Snapshot
Houston Chronicle
FREMONT, Calif. (AP) — FREMONT, Calif. (AP) — Personalis Inc. (PSNL) on Wednesday reported a loss of $13 million in its first quarter.
1 week ago
Personalis to Announce First Quarter 2024 Financial Results
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2024...
3 weeks ago
4 Analysts Have This To Say About Personalis - Personalis (NASDAQ:PSNL)
Benzinga
Personalis. PSNL+4.79%. + Free Alerts. underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish...
6 days ago
Cura Personalis and Generative AI in Education - Markkula Center for Applied Ethics
Santa Clara University
Cura personalis prompts us to consider the “care for the mind, body and spirit” of all of those involved in the world of higher education. The...
5 months ago
Personalis to cut workforce, forms new collaboration with Tempus
LabPulse.com
In a strategy intended to cut costs, cancer genomics company Personalis has approved a layoff of up to 65 employees, approximately 20% of...
5 months ago
Personalis Lands Tempus as Partner to Co-Commercialize Its MRD Test in Lung and Breast Cancer
Inside Precision Medicine
Personalis is partnering with AI-driven precision medicine company Tempus to co-commercialize its MRD test in lung and breast cancer.
5 months ago